Ucb Biopharma S/a

What Ucb Biopharma S/a does

UCB Biopharma S/A operates in Brazil as UCB Biopharma LTDA, a wholly-owned subsidiary of UCB S.A., a publicly traded Belgian biopharmaceutical company (Euronext Brussels: UCB) headquartered in Brussels and founded in 1923. The company develops and commercializes prescription biopharmaceutical products focused on two therapeutic verticals: neurology (primarily epilepsy, including rare syndromes such as Dravet syndrome) and immunology (rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, plaque psoriasis, hidradenitis suppurativa, and Crohn's disease). Its Brazil operations are anchored by a regional headquarters in São Paulo (Av. Presidente Juscelino Kubitschek, 1327) and supported by global R&D centers and manufacturing sites owned by the parent.

In Brazil, UCB Biopharma's commercial surface consists of three branded assets: UCBCares, a digital platform delivering selected medical articles and videos to healthcare professionals (neurologists, rheumatologists, dermatologists); Sempre em Frente, a patient support program bundling nutrition guidance, emotional support, and treatment assistance for immunology patients; and Compromisso Saúde, a parallel patient support program for epilepsy patients providing educational content, reminders, and adherence support. Distribution of prescription products runs through healthcare systems, hospitals, clinics, and pharmacies nationwide, complemented by direct-to-patient access through these programs. Pricing is not publicly disclosed, following standard prescription pharmaceutical economics.

The company engages in enterprise field sales targeted at prescribers and operates an ecosystem of digital content, blog articles, and social media channels (LinkedIn, Instagram, Facebook) for HCP and patient engagement. A minor GTM partnership exists with Vianews for press relations. UCB Biopharma is privately held as a subsidiary; financials are not separately disclosed, and its operations are part of UCB S.A.'s broader 30+-country footprint spanning Europe, North America, Asia-Pacific, and Latin America.

Name

Ucb Biopharma S/a

Legal name

UCB Biopharma LTDA

Website

https://ucb-biopharma.com.br

Company type

Private

Operating status

Operating

Headcount range

1–10 employees

Short description

UCB Biopharma S/A is the Brazilian subsidiary of Belgian biopharmaceutical company UCB S.A., developing and commercializing prescription drugs for neurology (epilepsy) and immunology (rheumatoid arthritis, psoriasis, psoriatic arthritis, hidradenitis suppurativa) in Brazil, with São Paulo as its Latin American regional headquarters.

Ownership category

akta.pro rank

Headquarters

HQ city

São Paulo

HQ country

Brazil

HQ region

Latin America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Marketing or Sales, Operations, Personnel

Revenue model

1. Prescription Pharmaceuticals: UCB develops and sells prescription biopharmaceutical products for neurological and immunological conditions, distributed through healthcare systems and pharmacies in Brazil and globally.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

UCB Biopharma S/A is the Brazilian subsidiary of UCB S.A. (Brussels, Belgium) that develops, manufactures, and commercializes specialty prescription medicines for severe neurological conditions (epilepsy, Parkinson's disease) and immunological/rheumatologic diseases. The company supplements its pharmaceutical portfolio with patient support programs (Compromisso Saúde, Sempre em Frente) and the UCBCares digital platform to assist patients managing chronic conditions.

Product overview

UCB Biopharma S/A is a global biopharmaceutical company focused on neurology and immunology. The company develops medications for serious neurological and immunological conditions including epilepsy (with specific focus on Dravet syndrome), rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, hidradenitis suppurativa, and plaque psoriasis. UCB's product portfolio in Brazil is complemented by patient support programs — Sempre em Frente (for immunology conditions) and Compromisso Saúde (for epilepsy) — and the UCBCares digital platform providing medical content for healthcare professionals. The company does not offer a unified software platform but rather distinct therapeutic area solutions and patient-facing digital support services.

Differentiator

Problem solved

Functional benefit

Brands

• UCBCares: Platform offering selected medical content — articles and videos — developed to support clinical practice with innovation and excellence. Healthcare professionals can register and deepen their knowledge journey in a digital environment designed for their needs.
• Programa Sempre em Frente
• Programa Compromisso Saúde

Products and services

• Compromisso Saúde Patient support program in Brazil designed to assist patients prescribed UCB medicines with treatment adherence, education, and access for chronic neurological and immunological conditions.
• Sempre em Frente Patient support program offered by UCB Biopharma in Brazil to help patients manage chronic conditions treated with UCB medications, providing adherence support and ancillary services.
• UCBCares Digital healthcare platform by UCB Biopharma in Brazil that provides patients prescribed UCB medicines with digital tools, information, and support services to manage their treatment.

Quantifiable outcome

• Comprehensive patient support programs for immunological and neurological conditions
• +1 more outcomes

Segments7 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

One partnership is on record.

• VianewsminorGTM or Marketing PartnerVianews is the press agency handling UCB's media relations in Brazil, providing official information requests and institutional materials to media outlets. Contact: Cristina Camarena, Alexandre Lyra, Michelly Siqueira.

Scale indicators1 record

Recent moves5 records

Expansion highlights4 records

Broad incumbents

• Pfizer Inc. Global biopharmaceutical incumbent with established neurology and immunology portfolios (e.g., Xeljanz in immunology; neurology assets post-Wyeth integration). Competes with UCB in Brazil's hospital and specialty channels.
• Novartis AG: Global biopharma with significant neurology and immunology assets (e.g., Cosentyx in immunology; neurology via gene therapy). Comparable broad-portfolio incumbent competing with UCB across multiple therapeutic areas in Brazil.
• Amgen Inc. Leading biologics manufacturer with immunology franchises (Enbrel, Otezla, Tezspire) overlapping with UCB's RA, psoriasis, and severe asthma-adjacent indications. Comparable biologics manufacturing and specialty distribution model.
• AbbVie Inc. Global biopharma with a leading immunology franchise (Humira, Skyrizi, Rinvoq) spanning RA, psoriatic arthritis, axial spondyloarthritis, psoriasis, and HS. Direct competitor to UCB across all major immunology indications in Brazil and globally.
• Sanofi: Global biopharma with Dupixent (dupilumab) co-developed with Regeneron — a leading biologic in atopic dermatitis, asthma, CRSwNP, and expanding into HS, eosinophilic esophagitis, and other indications. Overlaps with UCB's immunology and neurology positioning.
• F. Hoffmann-La Roche AG: Global biopharma with major neurology (Ocrevus in MS) and immunology (Actemra, Xolair) franchises. Comparable in scale and biologic-manufacturing depth; competes with UCB for specialty neurology and immunology share in Brazil.
• GSK plc: Global biopharma with immunology (Benlysta) and specialty neurology assets, plus strong emerging-markets presence in Brazil. Comparable broad-incumbent peer competing with UCB in both neurology and immunology therapeutic areas.

Direct peers

• Eisai Co., Ltd. Japanese global pharma with a focused neurology franchise including epilepsy (Fycompa/perampanel, Inovelon/rufinamide for Lennox-Gastaut). Direct competitor to UCB in epilepsy and rare seizure syndromes across global markets including Latin America.
• Biogen Inc. Neurology-focused biopharma with established epilepsy and rare neurological disease franchises. Comparable to UCB's specialty neurology positioning, business model, and prescriber base (neurologists).
• Jazz Pharmaceuticals plc: Specialty biopharma focused on neurology (epilepsy — Epidiolex/CBD for Dravet and Lennox-Gastaut syndromes) and psychiatry. Directly competes with UCB's neurology franchise in rare pediatric epilepsies including Dravet syndrome.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights5 records

Customer concentration

• Facebookfacebook.com/UCBBiopharmaBrasil
• LinkedInlinkedin.com/company/ucb-biopharma-brasil
• Instagraminstagram.com/ucb_brasil

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ucb Biopharma S/a